Amy L. Burroughs - 03 Jan 2023 Form 4 Insider Report for DiaMedica Therapeutics Inc. (DMAC)

Reporting relationship: Director
Issuer ticker: DMAC
Reported as of: 03 Jan 2023
Net transaction value: +$26,249
SEC form: 4
Accepted by SEC: 03 Jan 2023, 15:36:27 UTC
Prior SEC filing: 07 Dec 2022
Next SEC filing: 12 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Amy Culbert, attorney-in-fact

Key filing fact

Amy L. Burroughs filed Form 4 for DiaMedica Therapeutics Inc. (DMAC) on 03 Jan 2023.

Key facts

This page summarizes Amy L. Burroughs's Form 4 filing for DiaMedica Therapeutics Inc. (DMAC).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 03 Jan 2023, 15:36.

Change

Previous filing in this sequence was filed on 07 Dec 2022.
Current net transaction value: +$26,249.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DMAC transaction

Voting Common Shares, no par value per share

Award

Transaction value: $26,249
Shares: +17,156
Change %: +31%
Price: $1.53
Shares after: 73,288
Date: 03 Jan 2023
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $26,250.

Footnote F2

Includes 28,338 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan.